Business Context and Reporting Period
This Form 8-K is a current report filed by Scilex Holding Company (SCLX) on November 19, 2024. The filing addresses a critical change in the Company's independent registered public accounting firm and the resulting implications for its financial reporting status, specifically regarding the unaudited financial statements for the quarter ended September 30, 2024.
Key Financial Metrics and Liquidity
The filing does not provide specific revenue, profit, cash flow, or margin figures for the current period. However, it highlights significant liquidity and debt risks:
- Debt Obligations: The Company holds a senior secured promissory note issued to Oramed Pharmaceuticals Inc. (the "Oramed Note") and Tranche B senior secured convertible notes issued to institutional investors and Oramed (the "Tranche B Notes").
- Liquidity Risk: The Company's ability to conduct certain types of financings is currently limited or unavailable until the Q3 Form 10-Q is filed.
- Going Concern: Previous audit reports by Ernst & Young LLP (EY) for fiscal years 2022 and 2023 included a qualification regarding the Company's ability to continue as a going concern.
Material Changes and Events
The primary material event reported is the dismissal of the Company's independent auditor, Ernst & Young LLP (EY), effective immediately on November 19, 2024. This action was taken because EY could not provide assurance on the timely completion of its review of the Q3 2024 financial statements. The review was stalled due to an ongoing investigation by the Audit Committee into specific contracts entered into in June and September 2024, including a Commitment Side Letter with FSF 33433 LLC, a distribution agreement with Endeavor Distribution LLC, and a Satisfaction Agreement. These contracts may materially impact the financial statements for the quarters ended June 30, 2024, and September 30, 2024.
Outlook, Risks, and Contingencies
Management and the Audit Committee face several immediate risks and contingencies:
- Delisting Risk: Due to the failure to file the Q3 Form 10-Q, the Company expects to receive a notice from Nasdaq regarding non-compliance with continued listing requirements (Listing Rule 5250(c)(1)).
- Event of Default: The failure to file the Q3 Form 10-Q places the Company in default under the Oramed Note and Tranche B Notes. This could trigger accelerated payment of obligations, penalty interest, and liquidated damages unless lenders waive the default.
- Investigation Timeline: The Audit Committee's investigation, assisted by independent counsel, is expected to take at least several weeks to complete. No conclusive findings have been made yet.
- Future Reporting: The Company is in the process of identifying a new independent registered public accounting firm but cannot predict when the Q3 Form 10-Q will be filed.
Investor Verification Checklist
- Verify the status of the Audit Committee's investigation into the June and September 2024 contracts and whether findings will require restatement of Q2 or Q3 2024 financials.
- Confirm whether the holders of the Oramed Note and Tranche B Notes have issued a waiver regarding the event of default triggered by the late Q3 filing.
- Monitor communications from Nasdaq regarding the Company's compliance status and potential delisting proceedings.
- Track the engagement of a new independent registered public accounting firm and their ability to review the Q3 financials.
- Review the Company's cash position and ability to meet debt obligations if acceleration clauses are triggered.